type i il-1 receptor (il-1ri) as potential new therapeutic target for bronchial asthmai型il - 1受体(il-1ri)作为潜在的治疗支气管哮喘的新目标.pdf

Hindawi Publishing Corporation Mediators of Inflammation Volume 2010, Article ID 567351, 7 pages doi:10.1155/2010/567351 Review Article Type I IL-1 Receptor (IL-1RI) as Potential New Therapeutic Target for Bronchial Asthma Jyh-Hong Lee,1 Li-Chieh Wang,1 Hsin-Hui Yu,1 Yu-Tsan Lin,1 Yao-Hsu Yang,1 and Bor-Luen Chiang1, 2 1 Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100, Taiwan 2 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan Correspondence should be addressed to Bor-Luen Chiang, gicmbor@.tw Received 15 December 2009; Revised 26 March 2010; Accepted 31 May 2010 Academic Editor: Philipp Lepper Copyright © 2010 Jyh-Hong Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The IL-1R/TLR family has been receiving considerable attention as potential regulators of inflammation through their ability to act as either activators or suppressors of inflammation. Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness, allergic inflammation, elevated serum total, allergen-specific IgE levels, and increased Th2 cytokine production. The discovery that the IL-1RI–IL-1 and ST2–IL-33 pathways are crucial for allergic inflammation has raised interest in these receptors as potential targets for developing new therapeutic strategies for bronchial asthma. This paper discusses the current use of neutralizing mAb or soluble receptor constructs to deplete cytokines, the use of neutralizing mAb or recombinant receptor antago